Cognitive impairment in CKD patients: a guidance document by the CONNECT network

Basit Öğe Kaydı
dc.contributor.authorBolignano, Davide
dc.contributor.authorSimeoni, Mariadelina
dc.contributor.authorHafez, Gaye
dc.contributor.authorPepin, Marion
dc.contributor.authorGallo, Antonio
dc.contributor.authorAltieri, Manuela
dc.contributor.authorLiabeuf, Sophie
dc.contributor.authorGiannakou, Konstantinos
dc.contributor.authorDe, Ananya
dc.contributor.authorCapasso, Giovambattista
dc.date.accessioned2025-05-12T09:06:58Z
dc.date.available2025-05-12T09:06:58Z
dc.date.issued2025
dc.departmentFakülteler, Eczacılık Meslek Bilimleri Bölümü, Farmakoloji Ana Bilim Dalı
dc.description.abstractCognitive impairment is a prevalent and debilitating complication in patients with chronic kidney disease (CKD). This position paper, developed by the Cognitive Decline in Nephro-Neurology: European Cooperative Target network, provides guidance on the epidemiology, risk factors, pathophysiology, diagnosis and clinical management of CKD-related cognitive impairment. Cognitive impairment is significantly more common in CKD patients compared with the general population, particularly those undergoing haemodialysis. The development of cognitive impairment is influenced by a complex interplay of factors, including uraemic neurotoxins, electrolytes and acid-base disorders, anaemia, vascular damage, metabolic disturbances and comorbidities like diabetes and hypertension. Effective screening and diagnostic strategies are essential for early identification of cognitive impairment utilizing cognitive assessment tools, neuroimaging and circulating biomarkers. The impact of various drug classes, including antiplatelet therapy, oral anticoagulants, lipid-lowering treatments and antihypertensive drugs, on cognitive function is evaluated. Management strategies encompass pharmacological and non-pharmacological interventions, with recommendations for optimizing cognitive function while managing CKD-related complications. This guidance highlights the importance of addressing cognitive impairment in CKD patients through early detection, careful medication management and tailored therapeutic strategies to improve patient outcomes.
dc.identifier.citationBolignano, D., Simeoni, M., Hafez, G., Pepin, M., Gallo, A., Altieri, M., ... & Capasso, G. (2025). Cognitive impairment in CKD patients: a guidance document by the CONNECT network. Clinical Kidney Journal, 18(2), sfae294.
dc.identifier.doi10.1093/ckj/sfae294
dc.identifier.issn2048-8505
dc.identifier.issn2048-8513
dc.identifier.issue2
dc.identifier.pmid40235626
dc.identifier.scopus2-s2.0-85214390837
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://hdl.handle.net/20.500.12939/5741
dc.identifier.volume18
dc.identifier.wosWOS:001419742700001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.institutionauthorHafez, Gaye
dc.language.isoen
dc.relation.ispartofCONNECT Action Cognitive Declinein Nephroneurology European Cooperative
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCKD
dc.subjectcognitive impairment
dc.subjectneuroimaging
dc.subjectquality of life
dc.subjecturaemic neurotoxins
dc.titleCognitive impairment in CKD patients: a guidance document by the CONNECT network
dc.typeOther

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Eczacılık Fakültesi Yayın Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu